Results 51 to 60 of about 165,269 (210)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis [PDF]

Korean Journal of Pediatrics, 2011
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder that results from mutations in the TSC1 or TSC2 genes, and is associated with hamartomas in several organs, including subependymal giant cell tumors.
Won Seop Kim
doaj   +1 more source

Impact of mTOR signaling pathway on CD8+ T cell immunity through Eomesodermin in response to invasive candidiasis

Journal of Microbiology, Immunology and Infection, 2021
Background: We investigated the effect of the mammalian target of rapamycin (mTOR) pathway on CD8+ T cell immunity through Eomesodermin (Eomes) in intensive care unit (ICU) patients with invasive candidiasis (IC) and in a mouse model.
Jiahui Zhang, Na Cui, Hao Wang, Wen Han, Guangxu Bai, Wei Cheng   +5 more
doaj   +1 more source

Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases

Biomedical Journal, 2014
The mammalian target of rapamycin (mTOR) pathway is an essential cellular signaling pathway involved in a number of important physiological functions, including cell growth, proliferation, metabolism, protein synthesis, and autophagy.
Michael Wong
doaj   +1 more source

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. [PDF]

, 2018
Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension ...
Ayon, Ramon J, Balistrieri, Angela, Black, Stephen M, Chen, Jiwang, Desai, Ankit A, Garcia, Joe GN, Gu, Yali, Makino, Ayako, Rischard, Franz, Song, Shanshan, Tang, Haiyang, Vanderpool, Rebecca, Vinjamuri, Sujana, Wang, Jian, Wang, Ziyi, Wu, Kang, Yuan, Jason X-J, Zhang, Qian, Zhou, Guofei   +18 more
core   +1 more source

The replicative lifespan-extending deletion of SGF73 results in altered ribosomal gene expression in yeast. [PDF]

, 2017
Sgf73, a core component of SAGA, is the yeast orthologue of ataxin-7, which undergoes CAG-polyglutamine repeat expansion leading to the human neurodegenerative disease spinocerebellar ataxia type 7 (SCA7).
Garza, Renee M, Kennedy, Brian K, La Spada, Albert R, Mason, Amanda G, McCormick, Mark A, Patel, Bhumil, Pillus, Lorraine   +6 more
core   +2 more sources

Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells

Drug Design, Development and Therapy, 2013
Zhi-Jun Dai,1,* Jie Gao,2,* Hua-Feng Kang,1,* Yu-Guang Ma,1 Xiao-Bin Ma,1 Wang-Feng Lu,1 Shuai Lin,1 Hong-Bing Ma,1 Xi-Jing Wang,1 Wen-Ying Wu3 1Department of Oncology, 2Department of Nephrology, 3Department of Pharmacology, Second Affiliated Hospital ...
Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB, Lu WF, Lin S, Ma HB, Wang XJ, Wu WY   +9 more
doaj  

Rapamycin Rescues the Poor Developmental Capacity of Aged Porcine Oocytes [PDF]

Asian-Australasian Journal of Animal Sciences, 2014
Unfertilized oocytes age inevitably after ovulation, which limits their fertilizable life span and embryonic development. Rapamycin affects mammalian target of rapamycin (mTOR) expression and cytoskeleton reorganization during oocyte meiotic maturation ...
Seung Eun Lee, Eun Young Kim, Hyun Yong Choi, Jeremiah Jiman Moon, Min Jee Park, Jun Beom Lee, Chang Jin Jeong, Se Pill Park   +7 more
doaj   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial

Trials, 2019
Background Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions in children and adults. They present as clusters of vesicles full of lymph and blood to various extents, inducing maceration, esthetic impairment, pain, and impaired ...
Sophie Leducq, Agnès Caille, Sébastien Barbarot, Nathalie Bénéton, Didier Bessis, Olivia Boccara, Anne-Claire Bursztejn, Christine Chiaverini, Anne Dompmartin, Catherine Droitcourt, Valérie Gissot, Dominique Goga, Laurent Guibaud, Denis Herbreteau, Anne Le Touze, Christine Léauté-Labrèze, Gérard Lorette, Stéphanie Mallet, Ludovic Martin, Juliette Mazereeuw-Hautier, Alice Phan, Patrice Plantin, Isabelle Quéré, Pierre Vabres, Hélène Bourgoin, Bruno Giraudeau, Annabel Maruani, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique   +27 more
doaj   +1 more source

Mammalian EAK-7 activates alternative mTOR signaling to regulate cell proliferation and migration. [PDF]

, 2018
Nematode EAK-7 (enhancer-of-akt-1-7) regulates dauer formation and controls life span; however, the function of the human ortholog mammalian EAK-7 (mEAK-7) is unknown.
Fox, Alexandra Lucienne, Kim, Jin Koo, Krebsbach, Paul H, Mendonça, Daniela Baccelli, Nguyen, Joe Truong, Ray, Connor   +5 more
core   +2 more sources